Giuliana Minani Bertolino

Dr. Giuliana Minani Bertolino

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SMSotiris Mastoridis
Sotiris Mastoridis
GBGiuliana Minani Bertolino
Giuliana Minani Bertolino
GWGavin Whitehouse
Gavin Whitehouse
FDFrancesco Dazzi
Francesco Dazzi
ASAlberto Sanchez-Fueyo
Alberto Sanchez-Fueyo
MMMarc Martinez-Llordella
Marc Martinez-Llordella
Extracellular vesicles (EVs) are responsible for a multitude of physiological functions, including immunomodulation. A heterogenous mixture of small EV (sEV) subsets, including putative exosomes, is derived when commonly used “exosome” isolation techniques are employed. Subset diversity relates in part to their different intracellular origins, and can be associated with distinct functional properties. Recent progress in the EV field has enabled the categorization of such subsets based on their surface composition. For the first time, we combine such emerging subset-specific markers with advanced imaging flow cytometry (iFCM) to perform high-throughput, multiparametric, vesicle-by-vesicle characterization, and functional assessment of specific small EV subsets, and exosomes in particular. The approach allows researchers to address three important applications. First, it is known that different isolation techniques result in the divergent recovery of particular vesicle subsets. Taking three commonly used “exosome” isolation techniques as test cases (ultracentrifugation, size-exclusion chromatography, and polymer-based precipitation), the capacity for convenient and accurate isolate compositional analysis by iFCM is demonstrated. The approach was able to corroborate and to quantify the known skewing of subtype recovery among different isolation approaches. Second, exosomes are a particularly widely studied EV subset. Applying exosome-specific markers to samples collected from an optimal clinical transplantation model, we verify the capacity for iFCM to detect exosomes in circulation, to establish their tissue of origin, and to provide insights as to their functional immunological potential. Finally, we describe a technique for establishing whether the transfer of a molecule of interest to a target cell is exosomally mediated. In so doing, we highlight the approach’s utility in assessing the functional impact of circulating exosomes and in identifying their targets. In conclusion, we set out a new methodological approach by which small extracellular vesicle subsets, exosomes in particular, can be conveniently and comprehensively investigated, thereby offering novel phenotypic and functional insights.

25 June 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
TCTik Shing Cheung
Tik Shing Cheung
GBGiuliana Minani Bertolino
Giuliana Minani Bertolino
CGChiara Giacomini
Chiara Giacomini
MBMartin Bornhäuser
Martin Bornhäuser
FDFrancesco Dazzi
Francesco Dazzi
AGAntonio Galleu
Antonio Galleu
The immunosuppressive activity of mesenchymal stromal cells (MSCs) in graft versus host disease (GvHD) is well-documented, but their therapeutic benefit is rather unpredictable. Prospective randomized clinical trials remain the only means to address MSC clinical efficacy. However, the imperfect understanding of MSC biological mechanisms has undermined patients' stratification and the successful design of clinical studies. Furthermore, although MSC efficacy seems to be dependent on patient-associated factors, the role of patients' signature to predict and/or monitor clinical outcomes remains poorly elucidated. The analysis of GvHD patient serum has identified a set of molecules that are associated with high mortality. However, despite their importance in defining GvHD severity, their role in predicting or monitoring response to MSCs has not been confirmed. A new perspective on the use of MSCs for GvHD has been prompted by the recent findings that MSCs are actively induced to undergo apoptosis by recipient cytotoxic cells and that this process is essential to initiate MSC-induced immunosuppression. This discovery has not only reconciled the conundrum between MSC efficacy and their lack of engraftment, but also highlighted the determinant role of the patient in promoting and delivering MSC immunosuppression. In this review we will revisit the extensive use of MSCs for the treatment of GvHD and will elaborate on the need that future clinical trials must depend on mechanistic approaches that facilitate the development of robust and consistent assays to stratify patients and monitor clinical outcomes.

4 September 2023 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
GBGiuliana Minani Bertolino
Giuliana Minani Bertolino
MMMarie Maumus
Marie Maumus
Christian JorgensenChristian Jorgensen
Christian Jorgensen
Daniele NoelDaniele Noel
Daniele Noel

1 June 2015 in Stem Cells and Development
Verified
Journal Article
Closed access
AAAna Valéria Gouveia de Andrade
Ana Valéria Gouveia de Andrade
GBGiuliana Minani Bertolino
Giuliana Minani Bertolino
JRJulia Riewaldt
Julia Riewaldt
KBKaren Bieback
Karen Bieback
JKJana Karbanova
Jana Karbanova
TTTorsten Tonn
Torsten Tonn
Recently, mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) have been suggested as an alternative to MSCs for the treatment of various inflammatory disorders. However, while a first case report observed beneficial therapeutic effects of repeated MSC-EV infusions in a patient with therapy-refractory graft-versus-host disease, in vitro findings revealed that MSC-EVs were significantly less immunosuppressive than their parental cells. In this study, we compared the immunosuppressive potency of MSCs derived from bone marrow (BM-MSCs) and adipose tissue (AT-MSCs), with their secreted EVs in a standardized lymphocyte proliferation assay (LPA). Both BM-MSCs and AT-MSCs exhibited a remarkable inhibition of lymphocyte proliferation (LP) (88.1%±1.5% and 75.5%±1.5%, respectively), while isolated EVs derived from them failed to suppress LP at dose levels up to 100 μg/mL. Thus, our data further substantiate previous reports suggesting that cell-cell contact plays an important role on the immunosuppressive potential mediated by MSCs. Hence, MSC-EVs are still a matter of debate and might not be a reasonable substitute for MSCs with regard to the immunosuppressive function. Collectively, these contrasting findings may also reflect the importance of relevant translational aspects when designing new studies. Standardization of MSC culture conditions before EV collection as well as isolation and characterization methods with regard to EV purity are urged. Moreover, before clinical use, dose-finding studies evaluating MSC-EV preparations in suitable preclinical models are warranted.

14 September 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
GBGiuliana Minani Bertolino
Giuliana Minani Bertolino
MMmarie maumus
marie maumus
Christian JorgensenChristian Jorgensen
Christian Jorgensen
Daniele NoelDaniele Noel
Daniele Noel
Extracellular vesicles (EVs) are being widely investigated as acellular therapeutics in regenerative medicine applications. EVs isolated from mesenchymal stromal cells (MSCs) are by far the most frequently used in preclinical models for diverse therapeutic applications, including inflammatory, degenerative, or acute diseases. Although they represent promising tools as cell-free therapeutic agents, one limitation to their use is related to the batch-to-batch unreliability that may arise from the heterogeneity between MSC donors. Isolating EVs from MSCs derived from induced pluripotent stem cells (iMSCs) might allow unlimited access to cells with a more stable phenotype and function. In the present review, we first present the latest findings regarding the functional aspects of EVs isolated from iMSCs and their interest in regenerative medicine for the treatment of various diseases. We will then discuss future directions for their translation to clinics with good manufacturing practice implementation.

5 April 2024 in Nature Reviews Rheumatology
Verified
Journal Article
Open access
PDF file
GBGiuliana Minani Bertolino
Giuliana Minani Bertolino
MMMarie Maumus
Marie Maumus
Christian JorgensenChristian Jorgensen
Christian Jorgensen
Daniele NoelDaniele Noel
Daniele Noel